IMR Press / CEOG / Volume 41 / Issue 6 / DOI: 10.12891/ceog14142014

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Review
Platelet-activating factor acetylhydrolase and premature ovarian failure
Show Less
1 Department of Obstetrics and Gynecology, West China Second Hospital, Chengdu (China)
These authors contributed equally.
Clin. Exp. Obstet. Gynecol. 2014, 41(6), 613–616; https://doi.org/10.12891/ceog14142014
Published: 10 December 2014
Abstract

Premature ovarian failure (POF) appears to be a complex disease entity with several underlying etiopathogenic contributions including the possibility of multiple distinctly different autoimmune mechanisms, in which inflammatory autoimmunity targeted to ovarianspecific germline antigens (e.g., zona pellucida proteins or Mater) or differentiation/regulatory factors (e.g. inhibin-alpha) were regarded as one of the most crucial factors. Platelet-activating factor (PAF) and PAF class oxidized phospholipids stimulate the occurrence and development of inflammation and atherosclerosis. PAF acetylhydrolase (PAF-AH) can hydrolyze PAF and PAF class oxidized phospholipids and eventually prevent the body from the damage of these inflammatory mediators. These findings indicate a potential relationship between PAF-AH and POF thus have major implications for the future health of women who suffer with premature ovarian failure.
Keywords
Premature ovarian failure (POF)
Platelet-activating factor (PAF)
PAF acetylhydrolase (PAF-AH)
Share
Back to top